Literature DB >> 26642338

Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD.

Z DeFilipp1, M Purcell1, W A C Harris1, D J Chandra2, C Gleason1, J Wrammert3, S Sarantopoulos4, E K Waller1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26642338     DOI： 10.1038/bmt.2015.304

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease.

Authors:  M Okamoto; A Okano; S Akamatsu; E Ashihara; T Inaba; H Takenaka; N Katoh; S Kishimoto; C Shimazaki
Journal:  Leukemia       Date:  2006-01       Impact factor: 11.528

2.  Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.

Authors:  Silvia Svegliati Baroni; Mariarosaria Santillo; Federica Bevilacqua; Michele Luchetti; Tatiana Spadoni; Matteo Mancini; Paolo Fraticelli; Paola Sambo; Ada Funaro; Andrius Kazlauskas; Enrico V Avvedimento; Armando Gabrielli
Journal:  N Engl J Med       Date:  2006-06-22       Impact factor: 91.245

3.  Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Whitney S Washel; Nazmim S Bhuiya; Corey S Cutler; Edwin P Alyea; Vincent T Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

Review 4.  Aberrant B-cell homeostasis in chronic GVHD.

Authors:  Stefanie Sarantopoulos; Jerome Ritz
Journal:  Blood       Date:  2015-02-02       Impact factor: 22.113

Review 5.  Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis.

Authors:  Mohamed A Kharfan-Dabaja; Asmita R Mhaskar; Benjamin Djulbegovic; Corey Cutler; Mohamad Mohty; Ambuj Kumar
Journal:  Biol Blood Marrow Transplant       Date:  2009-06-10       Impact factor: 5.742

6.  Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Barry E Storer; Stephanie J Lee; Paul A Carpenter; Brenda M Sandmaier; Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

7.  Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.

Authors:  David Saadoun; Michelle Rosenzwajg; Dan Landau; Jean Charles Piette; David Klatzmann; Patrice Cacoub
Journal:  Blood       Date:  2008-02-21       Impact factor: 22.113

8.  Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.

Authors:  Corey Cutler; Haesook T Kim; Bhavjot Bindra; Stefanie Sarantopoulos; Vincent T Ho; Yi-Bin Chen; Jacalyn Rosenblatt; Sean McDonough; Phandee Watanaboonyongcharoen; Philippe Armand; John Koreth; Brett Glotzbecker; Edwin Alyea; Bruce R Blazar; Robert J Soiffer; Jerome Ritz; Joseph H Antin
Journal:  Blood       Date:  2013-07-16       Impact factor: 22.113

9.  The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery.

Authors:  Francesca Patriarca; Cristina Skert; Alessandra Sperotto; Francesco Zaja; Edmondo Falleti; Rosalba Mestroni; Francesca Kikic; Elisabetta Calistri; Carla Filì; Antonella Geromin; Michela Cerno; Renato Fanin
Journal:  Exp Hematol       Date:  2006-03       Impact factor: 3.084

10.  Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Corey S Cutler; Nazmim S Bhuiya; Michael Schowalter; Vincent T Ho; Edwin P Alyea; John Koreth; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2009-01-23       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.